Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Single IM Doses of DTI-117 in Healthy Participants
NCT07882472Phase 1Recruiting
- Sponsor
- Dignify Therapeutics
- Start
- Oct 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DTI-117 in urinary retention and constipation (6 arms), sponsored by Dignify Therapeutics. Primary endpoints: Number of participants with adverse events up to 7 days, Number of participants with abnormal lab test results up to 7 days and 2 more. Started Oct 2026; status: recruiting.
02
Drugs
DTI-117
03
Conditions
urinary retentionconstipation
Beyond the preview
Go deeper on NCT07882472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07882472.